BIAF — BioAffinity Technologies Income Statement
0.000.00%
Last trade - 00:00
HealthcareMicro Cap
- $27.29m
- $25.67m
- $2.53m
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0 | 0 | 0.005 | 2.53 |
Cost of Revenue | ||||
Gross Profit | — | — | 0.004 | 0.792 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Total Operating Expenses | 2.6 | 1.97 | 3.8 | 10.5 |
Operating Profit | -2.6 | -1.97 | -3.8 | -7.97 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -7.27 | -6.32 | -8.15 | -7.92 |
Provision for Income Taxes | ||||
Net Income After Taxes | -7.27 | -6.33 | -8.15 | -7.94 |
Net Income Before Extraordinary Items | ||||
Net Income | -7.27 | -6.33 | -8.15 | -7.94 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Dilution Adjustment | ||||
Diluted Net Income | -7.27 | -6.33 | -8.15 | -7.94 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -2.66 | -2.38 | -1.84 | -0.907 |
Dividends per Share |